095700.KQ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 08:30):

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea...

Stats
Dagens volum	0.00
Gjennomsnittsvolum	219 958
Markedsverdi	318.75B
EPS	KRW0 ( 2024-02-08 )
Neste inntjeningsdato	( KRW229.00 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW8.74 (0.11%)

Volum Korrelasjon

Lang: -0.10 (neutral)

Kort: 0.08 (neutral)

Signal:(62.734) Neutral

Genexine, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Genexine, Inc. Korrelasjon - Valuta/Råvare

-0.38
( neutral )

-0.41
( neutral )

-0.03
( neutral )

-0.30
( neutral )

-0.17
( neutral )

0.54
( weak )

Genexine, Inc. Økonomi

Annual	2023
Omsetning:	KRW4.43B
Bruttogevinst:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2023
Omsetning:	KRW4.43B
Bruttogevinst:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2022
Omsetning:	KRW16.14B
Bruttogevinst:	KRW7.30B (45.26 %)
EPS:	KRW-1 326.23

Financial Reports:

No articles found.

Genexine, Inc.

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.